オンコロジーコンパニオン診断の市場規模、シェア、動向分析レポート：製品・サービス別、技術別、製品タイプ別、疾患タイプ別、最終用途別、地域別、セグメント予測、2024年～2030年

オンコロジーコンパニオン診断市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界のオンコロジーコンパニオン診断市場規模は、2024年から2030年まで8.7%のCAGRで拡大し、2030年までに83億8,000万米ドルに達すると予測されています。

コンパニオン診断薬によって重要なゲノム情報へのアクセスが拡大することで、情報に基づいた意思決定が可能になり、患者のための標的治療アプローチの設計が可能になるため、包括的なゲノム検査とオンコロジーコンパニオン診断の需要が増加しています。

グリベック（イマチニブ）やハーセプチン（トラスツズマブ）など、処方前にコンパニオン診断（CDx）検査を必要とする薬剤の上市により、オンコロジーコンパニオン診断の売上は増加しています。この成長は、臨床試験中の相当数のCDx関連がん治療薬のために、将来も続くと予想されます。CDxは、治療のための独占的または包括的な検査としての機能以外に、臨床試験における参加者選択の際にも重要な役割を果たしています。患者がバイオマーカーの標的を有していれば、新薬候補がより高い奏効率を示す可能性が高まるからです。

CDxの使用に伴う経済的インセンティブは、医薬品開発者に医薬品と診断テストを組み合わせることを促しています。しかし、診断薬メーカーは、一方では支払者／医療提供者から、他方では医薬品メーカーからの相反する要求に直面しています。また、規制機関は診断薬と医薬品の開発スケジュールを一致させるために厳しい政策をとっています。そのため、診断薬メーカーは、単一の診断薬と特定の薬剤のマッチングに焦点を当てるのではなく、CDx開発の範囲を広げることが期待されています。

オンコロジーコンパニオン診断市場レポートハイライト

• 2023年の市場シェアは、運動器補綴デバイスが42.8.0%以上を占め、視覚人工内耳がこれに続く。一方、網膜神経補綴は、普及率の上昇と製品革新に関する研究開発努力の増加により、最も急速に成長している市場セグメントの1つであることが確認されました。
• 脊髄刺激療法（SCS）分野は、虚血性疼痛、背部手術失敗症候群、複雑難治性疼痛症候群の治療に使用されるSCS療法の鎮痛特性により、49.2％以上の最大シェアを占めました。さらに、脊髄内および硬膜外マイクロ刺激による脚の運動誘発にも応用されています。さらに、この分野における技術的進歩が、近い将来の市場成長をさらに押し上げると予想されます。仙骨神経刺激（SNS）は、慢性難治性骨盤痛や神経因性膀胱への応用により、予測期間中に最も急成長が見込まれる分野です。
• アプリケーション分野では、パーキンソン病やてんかんの増加により、運動ニューロン障害が最大のセグメントを占めています。例えば、Parkinson's disease Foundationが2012年に発表した報告書によると、毎年約6万人の米国人がパーキンソン病と診断されており、この数は予測期間中にさらに増加すると予想され、このセグメントの成長に拍車をかけています。
• 2023年には、北米が神経人工器官市場全体の42.5%以上を占めました。これは、神経インプラント・メーカーが多く存在すること、研究開発投資額が高いこと、政府と民間機関の両方から資金が得られることによる。例えば、国防高等研究計画局（DARPA）や国立神経障害・脳卒中研究所（NIH）は、連邦機関と協力して、神経インプラントのさらなる開発のための研究開発イニシアチブを支援する資金を提供しています。
• アジア太平洋地域は、安全で効果的な医療処置を推進する多国籍ヘルスケアのイントロダクションと、消費者の意識レベルの上昇により、最も急成長している分野であると予想されています。
• 戦略的提携やM&Aは、予測期間中、業界の競争レベルを高く維持すると予想されます。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 オンコロジーコンパニオン診断市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場牽引要因分析
  • 市場抑制要因分析
• オンコロジーコンパニオン診断市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析

第4章 オンコロジーコンパニオン診断市場：製品とサービスの推定・動向分析

• 世界のオンコロジーコンパニオン診断市場：製品とサービスのダッシュボード
• 世界のオンコロジーコンパニオン診断市場：製品とサービスの変動分析
• 世界のオンコロジーコンパニオン診断市場：製品・サービス別収益
• 製品
• サービス

第5章 オンコロジーコンパニオン診断市場：技術推定・動向分析

• 世界のオンコロジーコンパニオン診断市場：技術ダッシュボード
• 世界のオンコロジーコンパニオン診断市場：技術変動分析
• 世界のオンコロジーコンパニオン診断市場：技術別収益
• ポリメラーゼ連鎖反応（PCR）
• 次世代シーケンシング（NGS）
• 免疫組織化学（IHC）
• インサイチューハイブリダイゼーション（ISH）/蛍光インサイチューハイブリダイゼーション（FISH）
• その他のテクノロジー

第6章 オンコロジーコンパニオン診断市場：疾患タイプの推定・動向分析

• 世界のオンコロジーコンパニオン診断市場：疾患タイプダッシュボード
• 世界のオンコロジーコンパニオン診断市場：疾患タイプの変動分析
• 世界のオンコロジーコンパニオン診断市場：疾患タイプ別収益
• 乳がん
• 非小細胞肺がん
• 大腸がん
• 白血病
• 悪性黒色腫
• 前立腺がん
• その他

第7章 オンコロジーコンパニオン診断市場：最終用途の推定・動向分析

• 世界のオンコロジーコンパニオン診断市場：最終用途ダッシュボード
• 世界のオンコロジーコンパニオン診断市場：最終用途変動分析
• 世界のオンコロジーコンパニオン診断市場：最終用途別収益
• 病院
• 病理学/診断研究室
• アカデミック医療センター

第8章 オンコロジーコンパニオン診断市場：地域別推定・動向分析

• 地域ダッシュボード
• 市場規模と予測動向分析、2018年から2030年
• 北米
• 欧州
• アジア太平洋
• ラテンアメリカ
• 中東・アフリカ

第9章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 企業/競合の分類
• ベンダー情勢
  • 主要販売代理店およびチャネルパートナーのリスト
  • 主要顧客
  • 主要企業の市場シェア分析、2023年
  • Agilent Technologies, Inc.
  • Illumina, Inc.
  • QIAGEN
  • Thermo Fisher Scientific Inc.
  • Foundation Medicine, Inc.
  • Myriad Genetics, Inc.
  • F. Hoffmann-La Roche Ltd.
  • BioMerieux
  • Abbott
  • Leica Biosystems
  • Guardant Health, Inc.
  • EntroGen, Inc.

List of Tables

• Table 1 List of Secondary Sources
• Table 2 List of Abbreviations
• Table 3 Global Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
• Table 4 Global Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
• Table 5 Global Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
• Table 6 Global Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
• Table 7 Global Oncology Companion Diagnostic, by Region, 2018 - 2030 (USD Million)
• Table 8 North America Oncology Companion Diagnostic, by Country, 2018 - 2030 (USD Million)
• Table 9 North America Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
• Table 10 North America Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
• Table 11 North America Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
• Table 12 North America Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
• Table 13 U.S. Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
• Table 14 U.S. Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
• Table 15 U.S. Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
• Table 16 U.S. Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
• Table 17 Canada Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
• Table 18 Canada Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
• Table 19 Canada Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
• Table 20 Canada Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
• Table 21 Mexico Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
• Table 22 Mexico Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
• Table 23 Mexico Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
• Table 24 Mexico Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
• Table 25 Europe Oncology Companion Diagnostic, by Country, 2018 - 2030 (USD Million)
• Table 26 Europe Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
• Table 27 Europe Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
• Table 28 Europe Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
• Table 29 Europe Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
• Table 30 Germany Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
• Table 31 Germany Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
• Table 32 Germany Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
• Table 33 Germany Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
• Table 34 UK Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
• Table 35 UK Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
• Table 36 UK Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
• Table 37 UK Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
• Table 38 France Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
• Table 39 France Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
• Table 40 France Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
• Table 41 France Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
• Table 42 Italy Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
• Table 43 Italy Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
• Table 44 Italy Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
• Table 45 Italy Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
• Table 46 Spain Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
• Table 47 Spain Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
• Table 48 Spain Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
• Table 49 Spain Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
• Table 50 Denmark Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
• Table 51 Denmark Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
• Table 52 Denmark Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
• Table 53 Denmark Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
• Table 54 Sweden Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
• Table 55 Sweden Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
• Table 56 Sweden Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
• Table 57 Sweden Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
• Table 58 Norway Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
• Table 59 Norway Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
• Table 60 Norway Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
• Table 61 Norway Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
• Table 62 Asia Pacific Oncology Companion Diagnostic, by Country, 2018 - 2030 (USD Million)
• Table 63 Asia Pacific Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
• Table 64 Asia Pacific Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
• Table 65 Asia Pacific Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
• Table 66 Asia Pacific Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
• Table 67 China Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
• Table 68 China Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
• Table 69 China Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
• Table 70 China Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
• Table 71 Japan Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
• Table 72 Japan Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
• Table 73 Japan Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
• Table 74 Japan Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
• Table 75 India Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
• Table 76 India Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
• Table 77 India Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
• Table 78 India Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
• Table 79 South Korea Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
• Table 80 South Korea Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
• Table 81 South Korea Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
• Table 82 South Korea Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
• Table 83 Australia Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
• Table 84 Australia Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
• Table 85 Australia Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
• Table 86 Australia Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
• Table 87 Thailand Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
• Table 88 Thailand Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
• Table 89 Thailand Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
• Table 90 Thailand Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
• Table 91 Latin America Oncology Companion Diagnostic, by Country, 2018 - 2030 (USD Million)
• Table 92 Latin America Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
• Table 93 Latin America Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
• Table 94 Latin America Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
• Table 95 Latin America Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
• Table 96 Brazil Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
• Table 97 Brazil Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
• Table 98 Brazil Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
• Table 99 Brazil Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
• Table 100 Argentina Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
• Table 101 Argentina Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
• Table 102 Argentina Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
• Table 103 Argentina Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
• Table 104 Middle East & Africa Oncology Companion Diagnostic, by Country, 2018 - 2030 (USD Million)
• Table 105 Middle East & Africa Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
• Table 106 Middle East & Africa Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
• Table 107 Middle East & Africa Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
• Table 108 Middle East & Africa Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
• Table 109 South Africa Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
• Table 110 South Africa Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
• Table 111 South Africa Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
• Table 112 South Africa Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
• Table 113 Saudi Arabia Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
• Table 114 Saudi Arabia Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
• Table 115 Saudi Arabia Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
• Table 116 Saudi Arabia Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
• Table 117 UAE Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
• Table 118 UAE Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
• Table 119 UAE Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
• Table 120 UAE Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
• Table 121 Kuwait Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
• Table 122 Kuwait Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
• Table 123 Kuwait Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
• Table 124 Kuwait Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Information Procurement
• Fig. 3 Primary Research Pattern
• Fig. 4 Market Research Approaches
• Fig. 5 Value Chain-Based Sizing & Forecasting
• Fig. 6 Market Formulation & Validation
• Fig. 7 Oncology Companion Diagnostic Market Segmentation
• Fig. 8 Market Snapshot, 2023
• Fig. 9 Market Trends & Outlook
• Fig. 10 Market Driver Relevance Analysis (Current & Future Impact)
• Fig. 11 Market Restraint Relevance Analysis (Current & Future Impact)
• Fig. 12 Market Challenge Relevance Analysis (Current & Future Impact)
• Fig. 13 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
• Fig. 14 Porter's Five Forces Analysis
• Fig. 15 Global Oncology Companion Diagnostic Market: Product & Services Movement Analysis
• Fig. 16 Global Oncology Companion Diagnostic Market, for Product, 2018 - 2030 (USD Million)
• Fig. 17 Global Oncology Companion Diagnostic Market, for Services, 2018 - 2030 (USD Million)
• Fig. 18 Global Oncology Companion Diagnostic Market: Technology Movement Analysis
• Fig. 19 Global Oncology Companion Diagnostic Market, for Polymerase Chain Reaction (PCR), 2018 - 2030 (USD Million)
• Fig. 20 Global Oncology Companion Diagnostic Market, for Next-generation Sequencing (NGS), 2018 - 2030 (USD Million)
• Fig. 21 Global Oncology Companion Diagnostic Market, for Immunohistochemistry (IHC), 2018 - 2030 (USD Million)
• Fig. 22 Global Oncology Companion Diagnostic Market, for In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH), 2018 - 2030 (USD Million)
• Fig. 23 Global Oncology Companion Diagnostic Market, for Other Technologies, 2018 - 2030 (USD Million)
• Fig. 24 Global Oncology Companion Diagnostic Market: Disease Type Movement Analysis
• Fig. 25 Global Oncology Companion Diagnostic Market, for Breast Cancer, 2018 - 2030 (USD Million)
• Fig. 26 Global Oncology Companion Diagnostic Market, for Non-small Cell Lung Cancer, 2018 - 2030 (USD Million)
• Fig. 27 Global Oncology Companion Diagnostic Market, for Colorectal Cancer, 2018 - 2030 (USD Million)
• Fig. 28 Global Oncology Companion Diagnostic Market, for Leukemia, 2018 - 2030 (USD Million)
• Fig. 29 Global Oncology Companion Diagnostic Market, for Melanoma, 2018 - 2030 (USD Million)
• Fig. 30 Global Oncology Companion Diagnostic Market, for Prostate Cancer, 2018 - 2030 (USD Million)
• Fig. 31 Global Oncology Companion Diagnostic Market, for Others, 2018 - 2030 (USD Million)
• Fig. 32 Global Oncology Companion Diagnostic Market: End-use Movement Analysis
• Fig. 33 Global Oncology Companion Diagnostic Market, for Hospitals, 2018 - 2030 (USD Million)
• Fig. 34 Global Oncology Companion Diagnostic Market, for Pathology/Diagnostic Laboratory, 2018 - 2030 (USD Million)
• Fig. 35 Global Oncology Companion Diagnostic Market, for Academic Medical Center, 2018 - 2030 (USD Million)
• Fig. 36 Regional Marketplace: Key Takeaways
• Fig. 37 Regional Outlook, 2023 & 2030
• Fig. 38 Global Oncology Companion Diagnostic Market: Region Movement Analysis
• Fig. 39 North America Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
• Fig. 40 U.S. Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
• Fig. 41 Canada Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
• Fig. 42 Mexico Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
• Fig. 43 Europe Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
• Fig. 44 Germany Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
• Fig. 45 UK Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
• Fig. 46 France Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
• Fig. 47 Italy Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
• Fig. 48 Spain Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
• Fig. 49 Denmark Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
• Fig. 50 Sweden Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
• Fig. 51 Norway Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
• Fig. 52 Asia Pacific Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
• Fig. 53 Japan Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
• Fig. 54 China Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
• Fig. 55 India Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
• Fig. 56 Australia Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
• Fig. 57 South Korea Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
• Fig. 58 Thailand Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
• Fig. 59 Latin America Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
• Fig. 60 Brazil Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
• Fig. 61 Argentina Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
• Fig. 62 Middle East and Africa Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
• Fig. 63 South Africa Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
• Fig. 64 Saudi Arabia Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
• Fig. 65 UAE Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
• Fig. 66 Kuwait Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)

Oncology Companion Diagnostic Market Growth & Trends:

The global oncology companion diagnostic market size is expected to reach USD 8.38 billion by 2030, expanding at a CAGR of 8.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. Expanding access to important genomic information with the aid of companion diagnostics enables informed decision making for designing the targeted treatment approaches for their patients, thereby increasing demand for comprehensive genomic testing and oncology companion diagnostics.

The commercial launch of drugs including Gleevec (imatinib) and Herceptin (trastuzumab) that require Companion Diagnostics (CDx) testing before prescription has increased revenue generation in the oncology companion diagnostics field. This growth is expected to continue in the future owing to a substantial number of CDx associated oncology drugs in clinical trials. Apart from functioning as exclusive or inclusive tests for therapies, CDx also plays a crucial role during participant selection in clinical trials. This is because there is an increased potential for a novel drug candidate to show a better response rate if the patient has its biomarker target.

The economic incentives associated with the use of CDx have encouraged drug developers to combine their drugs with diagnostic tests. However, the diagnostic manufacturers face conflicting demands from payers/providers on one hand and drug manufacturers on the other hand. The regulatory bodies also have stringent policies to align the development timelines of diagnostics and drugs. Therefore, the diagnostic companies are expected to broaden their scope of CDx development instead of focusing on the attainment of a match between a single diagnostic with a specific drug.

Oncology Companion Diagnostic Market Report Highlights:

• The motor prosthetic devices segment dominated in terms of revenue share and accounted for over 42.8.0% of the market in 2023, followed by visual cochlear implants. Whereas, retinal neuroprosthetics were identified as one of the fastest growing market segment owing to the rising penetration and the increasing R&D efforts pertaining to product innovation.
• The Spinal Cord Stimulation (SCS) segment held the largest share at over 49.2% owing to the analgesic property of the SCS therapy used in the treatment of ischemic pain, failed back surgery syndrome, and complex refractory pain syndrome. Furthermore, it finds applications in intraspinal and epidural microstimulation for inducing leg movements. In addition, technological advancements in this segment is expected to further boost market growth in the near future. The sacral Nerve Stimulation (SNS) is expected to be the fastest growing segment over the forecast period due to its applications in chronic intractable pelvic ache and neurogenic bladder.
• In the applications segment, motor neuron disorders held the largest segment due to the rising incidences of Parkinson's disease and epilepsy. For instance, as per the report published by Parkinson's disease Foundation in 2012, approximately 60,000 Americans were diagnosed with Parkinson's disease each year and the number is expected to grow further over the forecast period thereby fueling this segment's growth.
• In 2023, North America dominated the overall neuroprosthetics market at over 42.5% owing to the large presence of neural implants manufacturers, higher R&D investments, and the availability of funds from both government and private institutes. For instance, the Defense Advanced Research Project Agency (DARPA) and National Institute of Neurological Disorders and Stroke (NIH)in collaboration with the federal agencies are instrumental in providing funds to support R&D initiatives for the further development of neural implants.
• Asia Pacific is anticipated to be the fastest growing segment due to the introduction of multinational healthcare establishments promoting safe and effective medical procedures along with the rising awareness levels amongst consumers.
• Strategic collaborations and mergers & acquisitions are expected to keep the industry rivalry level high over the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product & Services
  • 1.2.2. Technology
  • 1.2.3. Disease Type
  • 1.2.4. End-use
  • 1.2.5. Regional scope
  • 1.2.6. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product & services and technology outlook
  • 2.2.2. Disease type and end-use outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Oncology Companion Diagnostic Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing prevalence of cancer
    • 3.2.1.2. Growing adoption of companion diagnostics
    • 3.2.1.3. Rising emphasis on personalized medicine
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Complex regulatory landscape
    • 3.2.2.2. Limited awareness and adoption in developing countries
• 3.3. Oncology Companion Diagnostic Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Oncology Companion Diagnostic Market: Product & Services Estimates & Trend Analysis

• 4.1. Global Oncology Companion Diagnostic Market: Product & Services Dashboard
• 4.2. Global Oncology Companion Diagnostic Market: Product& Services Movement Analysis
• 4.3. Global Oncology Companion Diagnostic Market by Product& Services, Revenue
• 4.4. Product
  • 4.4.1. Product market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Instruments
    • 4.4.2.1. Product market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Consumables
    • 4.4.3.1. Consumables market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.4. Software
    • 4.4.4.1. Software market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Services
  • 4.5.1. Services market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Oncology Companion Diagnostic Market: Technology Estimates & Trend Analysis

• 5.1. Global Oncology Companion Diagnostic Market: Technology Dashboard
• 5.2. Global Oncology Companion Diagnostic Market: Technology Movement Analysis
• 5.3. Global Oncology Companion Diagnostic Market by Technology, Revenue
• 5.4. Polymerase Chain Reaction (PCR)
  • 5.4.1. Polymerase Chain Reaction (PCR) market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Next-generation Sequencing (NGS)
  • 5.5.1. Next-generation Sequencing (NGS) market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Immunohistochemistry (IHC)
  • 5.6.1. Immunohistochemistry (IHC) market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. In Situ Hybridization (ISH)/Fluorescence In Situ Hybridization (FISH)
  • 5.7.1. In Situ Hybridization (ISH)/Fluorescence In Situ Hybridization (FISH) market estimates and forecasts 2018 to 2030 (USD Million)
• 5.8. Other Technologies
  • 5.8.1. Other technologies market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Oncology Companion Diagnostic Market: Disease Type Estimates & Trend Analysis

• 6.1. Global Oncology Companion Diagnostic Market: Disease Type Dashboard
• 6.2. Global Oncology Companion Diagnostic Market: Disease Type Movement Analysis
• 6.3. Global Oncology Companion Diagnostic Market by Disease Type, Revenue
• 6.4. Breast Cancer
  • 6.4.1. Breast cancer market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Non-small Cell Lung Cancer
  • 6.5.1. Non-small cell lung cancer market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Colorectal Cancer
  • 6.6.1. Colorectal cancer market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. Leukemia
  • 6.7.1. Leukemia market estimates and forecasts 2018 to 2030 (USD Million)
• 6.8. Melanoma
  • 6.8.1. Melanoma market estimates and forecasts 2018 to 2030 (USD Million)
• 6.9. Prostate Cancer
  • 6.9.1. Prostate cancer market estimates and forecasts 2018 to 2030 (USD Million)
• 6.10. Others
  • 6.10.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Oncology Companion Diagnostic Market: End-use Estimates & Trend Analysis

• 7.1. Global Oncology Companion Diagnostic Market: End-use Dashboard
• 7.2. Global Oncology Companion Diagnostic Market: End-use Movement Analysis
• 7.3. Global Oncology Companion Diagnostic Market by End-use, Revenue
• 7.4. Hospitals
  • 7.4.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Pathology/Diagnostic Laboratory
  • 7.5.1. Pathology/Diagnostic laboratory market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Academic Medical Center
  • 7.6.1. Academic medical center market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Oncology Companion Diagnostic Market: Regional Estimates & Trend Analysis

• 8.1. Regional Dashboard
• 8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030
• 8.3. North America
  • 8.3.1. U.S.
    • 8.3.1.1. Key country dynamics
    • 8.3.1.2. Regulatory framework/ reimbursement structure
    • 8.3.1.3. Competitive scenario
    • 8.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.3.2. Canada
    • 8.3.2.1. Key country dynamics
    • 8.3.2.2. Regulatory framework/ reimbursement structure
    • 8.3.2.3. Competitive scenario
    • 8.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.3.3. Mexico
    • 8.3.3.1. Key country dynamics
    • 8.3.3.2. Regulatory framework/ reimbursement structure
    • 8.3.3.3. Competitive scenario
    • 8.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 8.4. Europe
  • 8.4.1. UK
    • 8.4.1.1. Key country dynamics
    • 8.4.1.2. Regulatory framework/ reimbursement structure
    • 8.4.1.3. Competitive scenario
    • 8.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.2. Germany
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Regulatory framework/ reimbursement structure
    • 8.4.2.3. Competitive scenario
    • 8.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.3. France
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Regulatory framework/ reimbursement structure
    • 8.4.3.3. Competitive scenario
    • 8.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.4. Italy
    • 8.4.4.1. Key country dynamics
    • 8.4.4.2. Regulatory framework/ reimbursement structure
    • 8.4.4.3. Competitive scenario
    • 8.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.5. Spain
    • 8.4.5.1. Key country dynamics
    • 8.4.5.2. Regulatory framework/ reimbursement structure
    • 8.4.5.3. Competitive scenario
    • 8.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.6. Norway
    • 8.4.6.1. Key country dynamics
    • 8.4.6.2. Regulatory framework/ reimbursement structure
    • 8.4.6.3. Competitive scenario
    • 8.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.7. Sweden
    • 8.4.7.1. Key country dynamics
    • 8.4.7.2. Regulatory framework/ reimbursement structure
    • 8.4.7.3. Competitive scenario
    • 8.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.8. Denmark
    • 8.4.8.1. Key country dynamics
    • 8.4.8.2. Regulatory framework/ reimbursement structure
    • 8.4.8.3. Competitive scenario
    • 8.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Japan
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework/ reimbursement structure
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.2. China
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework/ reimbursement structure
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.3. India
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework/ reimbursement structure
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.4. Australia
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory framework/ reimbursement structure
    • 8.5.4.3. Competitive scenario
    • 8.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.5. South Korea
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Regulatory framework/ reimbursement structure
    • 8.5.5.3. Competitive scenario
    • 8.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.6. Thailand
    • 8.5.6.1. Key country dynamics
    • 8.5.6.2. Regulatory framework/ reimbursement structure
    • 8.5.6.3. Competitive scenario
    • 8.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 8.6. Latin America
  • 8.6.1. Brazil
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework/ reimbursement structure
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.2. Argentina
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework/ reimbursement structure
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 8.7. MEA
  • 8.7.1. South Africa
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework/ reimbursement structure
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.2. Saudi Arabia
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework/ reimbursement structure
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.3. UAE
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework/ reimbursement structure
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.4. Kuwait
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework/ reimbursement structure
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis, By Key Market Participants
• 9.2. Company/Competition Categorization
• 9.3. Vendor Landscape
  • 9.3.1. List of key distributors and channel partners
  • 9.3.2. Key customers
  • 9.3.3. Key company market share analysis, 2023
  • 9.3.4. Agilent Technologies, Inc.
    • 9.3.4.1. Company overview
    • 9.3.4.2. Financial performance
    • 9.3.4.3. Product benchmarking
    • 9.3.4.4. Strategic initiatives
  • 9.3.5. Illumina, Inc.
    • 9.3.5.1. Company overview
    • 9.3.5.2. Financial performance
    • 9.3.5.3. Product benchmarking
    • 9.3.5.4. Strategic initiatives
  • 9.3.6. QIAGEN
    • 9.3.6.1. Company overview
    • 9.3.6.2. Financial performance
    • 9.3.6.3. Product benchmarking
    • 9.3.6.4. Strategic initiatives
  • 9.3.7. Thermo Fisher Scientific Inc.
    • 9.3.7.1. Company overview
    • 9.3.7.2. Financial performance
    • 9.3.7.3. Product benchmarking
    • 9.3.7.4. Strategic initiatives
  • 9.3.8. Foundation Medicine, Inc.
    • 9.3.8.1. Company overview
    • 9.3.8.2. Financial performance
    • 9.3.8.3. Product benchmarking
    • 9.3.8.4. Strategic initiatives
  • 9.3.9. Myriad Genetics, Inc.
    • 9.3.9.1. Company overview
    • 9.3.9.2. Financial performance
    • 9.3.9.3. Product benchmarking
    • 9.3.9.4. Strategic initiatives
  • 9.3.10. F. Hoffmann-La Roche Ltd.
    • 9.3.10.1. Company overview
    • 9.3.10.2. Financial performance
    • 9.3.10.3. Product benchmarking
    • 9.3.10.4. Strategic initiatives
  • 9.3.11. BioMerieux
    • 9.3.11.1. Company overview
    • 9.3.11.2. Financial performance
    • 9.3.11.3. Product benchmarking
    • 9.3.11.4. Strategic initiatives
  • 9.3.12. Abbott
    • 9.3.12.1. Company overview
    • 9.3.12.2. Financial performance
    • 9.3.12.3. Product benchmarking
    • 9.3.12.4. Strategic initiatives
  • 9.3.13. Leica Biosystems
    • 9.3.13.1. Company overview
    • 9.3.13.2. Financial performance
    • 9.3.13.3. Product benchmarking
    • 9.3.13.4. Strategic initiatives
  • 9.3.14. Guardant Health, Inc.
    • 9.3.14.1. Company overview
    • 9.3.14.2. Financial performance
    • 9.3.14.3. Product benchmarking
    • 9.3.14.4. Strategic initiatives
  • 9.3.15. EntroGen, Inc.
    • 9.3.15.1. Company overview
    • 9.3.15.2. Financial performance
    • 9.3.15.3. Product benchmarking
    • 9.3.15.4. Strategic initiatives